CompanyGraph
Zhejiang Haisen Pharmaceutical Co., Ltd.
001367 · SZSE · China
haisenpharma.comFinancials as of FY2025
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.59%
Annual Rate
CNY 0.12Paid annual
Payout Ratio
13.1%Sustainable
Last Ex-Dividend
May 13, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.01BCNY446.90M · vs all stocks (USD)
Trailing P/E
22.48xRevenue (TTM)
520.97MCNY77.26M · vs all stocks (USD)
Profit Margin
25.64%Beta
0.1300xvs all stocks
52-Week Change
-24.59%vs all stocks
Market Capitalization
3.01BCNY446.90M · vs all stocks (USD)
Enterprise Value
1.91BCNY283.36M · vs all stocks (USD)
Trailing P/E
22.48xPrice to Sales (TTM)
5.78xPrice to Book (MRQ)
1.97xEnterprise to Revenue
3.67xEnterprise to EBITDA
11.56xGross Margin
48.19%Profit Margin
25.64%Operating Margin
30.26%Return on Assets (TTM)
5.66%Return on Equity (TTM)
9.19%Revenue (TTM)
520.97MCNY77.26M · vs all stocks (USD)
Revenue per Share (TTM)
3.47CNYUpdated Aug 18, 2026Quarterly Revenue Growth
-9.50%Gross Profit (TTM)
240.29MCNY35.63M · vs all stocks (USD)
EBITDA (TTM)
158.60MCNY23.52M · vs all stocks (USD)
Net Income (TTM)
133.58MCNY19.81M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-7.40%Operating Cash Flow (TTM)
163.28MCNY24.21M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.28MCNY189.12K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1160CNYUpdated Aug 18, 2026Trailing Annual Dividend Yield
0.59%vs all stocks
Payout Ratio
13.05%Revenue
532.26MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
289.55MCNYFY2025 · Dec 31, 2025Gross Profit
242.71MCNYFY2025 · Dec 31, 2025Operating Income
148.56MCNY22.03M · vs all stocks (USD)
Pre-tax Income
156.76MCNYFY2025 · Dec 31, 2025Income Tax Expense
20.88MCNYFY2025 · Dec 31, 2025Net Income
135.88MCNYFY2025 · Dec 31, 2025EBIT
157.10MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
182.42MCNYFY2025 · Dec 31, 2025Research & Development
38.86MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
25.51MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
346.05KCNYFY2025 · Dec 31, 2025Net Income from Continuing Operations
135.88MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
118.87MCNYFY2025 · Dec 31, 2025Free Cash Flow
-33.39MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
900.01MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
135.88MCNYFY2025 · Dec 31, 2025Other Non-cash Items
866.02KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-16.48MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-152.26MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.09BCNYFY2025 · Dec 31, 2025Sale of Investments
1.94BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-297.25MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-17.45MCNYFY2025 · Dec 31, 2025Other Financing Charges
1.86MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-15.59MCNYFY2025 · Dec 31, 2025Shares Outstanding
152.35MSharesUpdated Aug 18, 2026Float Shares
40.12MSharesUpdated Aug 18, 2026% Held by Insiders
76.36%vs all stocks
% Held by Institutions
0.19%vs all stocks
Total Cash (MRQ)
1.07BCNY158.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
7.03CNYUpdated Aug 18, 2026Total Debt (MRQ)
7.51MCNY1.11M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0049xCurrent Ratio (MRQ)
14.65xBook Value per Share (MRQ)
10.03CNYUpdated Aug 18, 2026Total Assets
1.63BCNY241.76M · vs all stocks (USD)
Total Current Assets
1.28BCNYFY2025 · Dec 31, 2025Total Liabilities
136.48MCNYFY2025 · Dec 31, 2025Total Non-current Assets
349.42MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
20.18MCNYFY2025 · Dec 31, 2025Total Current Liabilities
116.30MCNYFY2025 · Dec 31, 2025Cash
909.33MCNYFY2025 · Dec 31, 2025Cash Equivalents
153.85KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
909.49MCNYFY2025 · Dec 31, 2025Other Short-term Investments
151.69MCNYFY2025 · Dec 31, 2025Accounts Receivable
86.30MCNYFY2025 · Dec 31, 2025Inventory
108.47MCNYFY2025 · Dec 31, 2025Accounts Payable
44.88MCNYFY2025 · Dec 31, 2025Short-term Debt
1.33MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.99MCNYFY2025 · Dec 31, 2025Long-term Debt
6.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
152.35MCNYFY2025 · Dec 31, 2025Retained Earnings
555.36MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.49BCNY221.52M · vs all stocks (USD)
Treasury Stock
18.86MCNYFY2025 · Dec 31, 202552-Week Low
16.78CNYUpdated Aug 18, 202652-Week High
28.00CNYUpdated Aug 18, 202652-Week Change
-24.59%vs all stocks
Beta
0.1300xvs all stocks
50-Day MA
18.98CNYUpdated Aug 18, 2026200-Day MA
22.27CNYUpdated Aug 18, 2026Avg 10-Day Volume
1.72MSharesUpdated Aug 18, 2026Avg 30-Day Volume
1.77MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
0.8800CNYUpdated Aug 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Pacific Biosciences of California, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Honz Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
YC Corp
1 interpretationPrice Below Mean With Profitability And Book Value
Shanghai Shyndec Pharmaceutical Co., Ltd.
1 interpretationPrice Below Mean With Profitability And Book Value
Ningbo Shuanglin Auto Parts Co., Ltd.
1 interpretationPrice Below Mean With Profitability And Book Value